SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

Blood

Volumn 126, Issue 2, 2015, Pages 233-241

  Malcovati, Luca ^a,b   Karimi, Mohsen ^c   Papaemmanuil, Elli ^d   Ambaglio, Ilaria ^a,b   Jädersten, Martin ^c   Jansson, Monika ^c   Elena, Chiara ^a,b   Gallì, Anna ^b   Walldin, Gunilla ^c   Porta, Matteo G Della ^a,b   Raaschou Jensen, Klas ^e   Travaglino, Erica ^b   Kallenbach, Klaus ^e   Pietra, Daniela ^b   Ljungström, Viktor ^f   Conte, Simona ^c   Boveri, Emanuela ^g   Invernizzi, Rosangela ^a,g   Rosenquist, Richard ^f   Campbell, Peter J ^d   Cazzola, Mario ^a,b   Lindberg, Eva Hellström ^c   more..

^a UNIVERSITY OF PAVIA   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e Copenhagen University Hospital ^*  (Denmark)

^f UPPSALA UNIVERSITY   (Sweden)

^g FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE COURSE; DNA METHYLATION; FEMALE; GENE; GENE SEQUENCE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH UNILINEAGE DYSPLASIA; SF3B1 GENE; SOMATIC MUTATION; ADOLESCENT; ANEMIA, SIDEROBLASTIC; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; GENETICS; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

PHOSPHOPROTEIN; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, SIDEROBLASTIC; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PHOSPHOPROTEINS; PROGNOSIS; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; YOUNG ADULT;

EID: 84937805127     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-633537     Document Type: Article

References (42)

1. Bjorkman SE. Chronic refractory anemia with sideroblastic bone marrow; a study of four cases. Blood. 1956;11(3):250-259.
2. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51(2):189-199.
3. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7): 2292-2302.
4. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood. 2009;114(5):937-951.
5. Papaemmanuil E, Cazzola M, Boultwood J, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15): 1384-1395.
6. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
7. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122(25):4021-4034.
8. Cazzola M, Rossi M, Malcovati L; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood. 2013; 121(2):260-269.
9. Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms. In: Swerdlow SHCE, Harris NL, Jaffe ES, et al, eds. WHO Classification of Tumors Of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:89-107.
10. Malcovati L, Papaemmanuil E, Bowen DT, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118(24):6239-6246.
11. Van Den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature. 1974;251(5474):437-438.
12. Papaemmanuil E, Gerstung M, Malcovati L, et al; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-3627, quiz 3699.
13. Malcovati L, Papaemmanuil E, Ambaglio I, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014;124(9):1513-1521.
14. Malcovati L, Hellstr öm-Lindberg E, Bowen D, et al; European Leukemia Net. Diagnosis and treatment of primary myelodysplastic syndromes in adults: Recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943-2964.
15. Vardiman JW, Brunning R, Arber DA, et al. Introduction and overview of the classification of the myeloid neoplasms. In: Swerdlow SHCE, Harris NL, Jaffe ES, et al, eds. WHO Classification of Tumors Of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
16. Harris NL, Campo E, Jaffe E, et al. Introduction to the classification of tumours of haematopoietic and lymphoid tissues. In: Swerdlow SHCE, Harris NL, Jaffe ES, et al, eds. WHO Classification of Tumors Of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:14-15.
17. Mufti GJ, Bennett JM, Goasguen J, et al; International Working Group on Morphology of Myelodysplastic Syndrome. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008;93(11):1712-1717.
18. Goasguen JE, Bennett JM, Bain BJ, Vallespi T, Brunning R, Mufti GJ; International Working Group on Morphology of Myelodysplastic Syndrome. Morphological evaluation of monocytes and their precursors. Haematologica. 2009;94(7):994-997.
19. Malcovati L, Della Porta MG, Pietra D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood. 2009;114(17): 3538-3545.
20. Rumi E, Pietra D, Ferretti V, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544-1551.
21. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med. 1993; 12(8):737-751.
22. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
23. Malcovati L, Germing U, Kuendgen A, et al. Timedependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25(23):3503-3510.
24. Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15): 3005-3015.
25. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-2465.
26. Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012; 119(2):569-572.
27. Broseús J, Alpermann T, Wulfert M, et al; MPN and MPNr-EuroNet (COST Action BM0902). Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2013;27(9): 1826-1831.
28. Woll PS, Kjällquist U, Chowdhury O, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell. 2014;25(6):794-808.
29. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
30. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009; 41(7):838-842.
31. Shlush LI, Zandi S, Mitchell A, et al; HALT Pan-Leukemia Gene Panel Consortium. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia [published correction appears in Nature. 2014;508(7496):420]. Nature. 2014; 506(7488):328-333.
32. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010; 468(7325):839-843.
33. Ambaglio I, Malcovati L, Papaemmanuil E, et al. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica. 2013;98(3): 420-423.
34. Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in b-thalassemia. Nat Med. 2014; 20(4):398-407.
35. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-b superfamily ligand trap ACE-536 corrects anemia by promoting latestage erythropoiesis. Nat Med. 2014;20(4): 408-414.
36. Platzbecker U, Germing U, Giagounidis A, et al. ACE-536 increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS): Preliminary results from a phase 2 study [abstract]. Blood. 2014;124(21). Abstract 411.
37. Gao Y, Vogt A, Forsyth CJ, Koide K. Comparison of splicing factor 3b inhibitors in human cells. ChemBioChem. 2013;14(1):49-52.
38. Yokoi A, Kotake Y, Takahashi K, et al. Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS J. 2011;278(24): 4870-4880.
39. Buonamici S, Perino S, Lim K, et al. Cancerassociated mutations in SF3B1 exhibit neomorphic splicing activity and block erythroid differentiation [abstract]. Blood. 2014;124(21). Abstract 4615.
40. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
41. Wang G, Fersht AR. First-order rate-determining aggregation mechanism of p53 and its implications. Proc Natl Acad Sci USA. 2012; 109(34):13590-13595.
42. Bykov VJ, Wiman KG. Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett. 2014;588(16):2622-2627.